舒洛地特联合缬沙坦对2型糖尿病肾病患者肾保护作用的随机对照临床试验OACSTPCD
Renal protective effects of sulodexide combined with valsartan in patients with type 2 diabetic nephropathy:a randomized controlled clinical trial
目的:探讨舒洛地特联合缬沙坦对2 型糖尿病肾病患者的肾保护作用及影响因素.方法:选取 2 型糖尿病肾病患者98 例,分为常规组(n =49)、研究组(n =49).常规组予以缬沙坦(80 mg/次,1 次/d)治疗3 个月,研究组在常规组基础上予以舒洛地特(250 LSU/次,2 次/d)治疗3 个月,比较两组疗效、不良反应发生率及治疗前、治疗3 个月后肾功能指标[尿素氮(BUN)、血清肌酐(Scr)、24 h尿蛋白]、糖脂代谢指标[空腹血糖(FPG)、甘油三酯(TG)、糖化血红蛋白(HbA1c)、总胆固醇(TC)],分析整体疗效的影响因素.结果:研究组治疗总有效率较常规组高(P =0.037),治疗后研究组BUN、Scr、24 h尿蛋白及FPG、HbA1c、TG、TC水平低于常规组(P<0.05).研究组不良反应发生率与常规组相比,差异无统计学意义(P =0.674).病程(OR =4.186,95%CI为 2.491~7.033)、肾小球硬化(OR =5.865,95%CI为4.216~8.159)、糖尿病肾病分期(OR =5.742,95%CI为 3.512~9.387)、合并高血压(OR =4.134,95%CI为2.455~6.960)、治疗方案(OR =5.597,95%CI为3.958~7.915)为整体疗效的影响因素(P<0.05).结论:舒洛地特联合缬沙坦治疗2 型糖尿病肾病疗效显著,可改善糖脂代谢,对肾功能具有保护作用,病程、糖尿病肾病分期、合并高血压、肾小球硬化、治疗方案均为影响患者整体疗效的相关因素.
Aim:To explore the renal protective effects of sulodexide combined with valsartan on type 2 diabetic ne-phropathy and its influencing factors.Methods:A total of 98 patients with type 2 diabetic nephropathy were selected and al-located into conventional group(n =49)and study group(n =49).The conventional group was treated with valsartan(80 mg per time,once per day),while the study group was treated with sulodexide on the basis of the conventional group(250 LSU per time,twice per day)for 3 months.The curative effects,incidence of adverse reactions,renal function indexes[urea nitro-gen(BUN),serum creatinine(Scr)and 24-hour urinary protein],glucose and lipid metabolism indexes[fasting blood glu-cose(FPG),triglyceride(TG),glycosylated hemoglobin(HbA1c)and total cholesterol(TC)]before and after treatment were compared between the 2 groups.The influencing factors on the overall curative effects were analyzed.Results:The to-tal effective rate of treatment in the study group was higher than that of the conventional group(P =0.037).After treat-ment,the levels of BUN,Scr,24-hour urinary protein,FPG,HbA1c,TG,and TC in the study group were lower than those in the conventional group(P<0.05).There was no significant difference in the incidence of adverse reactions between the 2 groups(P =0.674).The course of disease(OR =4.186,95%CI was 2.491-7.033),glomerulosclerosis(OR =5.865,95%CI was4.216-8.159),stages of diabetic nephropathy(OR = 5.742,95%CI was 3.512-9.387),hypertension(OR =4.134,95%CI was 2.455-6.960)and treatment plan(OR =5.597,95%CI was 3.958-7.915)were the influ-encing factors of overall curative effects(P<0.05).Conclusion:Sulodexide combined with valsartan has significant thera-peutic effects on type 2 diabetic nephropathy,which could improve glucose and lipid metabolism and protect renal function.The course of disease,stage of diabetic nephropathy,hypertension,glomerulosclerosis and treament plan are factors affecting the overall curative effects.
布海霞;郭利芹;徐可;王焕
新乡市中心医院(新乡医学院第四临床学院)肾内科 河南新乡 453000
临床医学
舒洛地特糖尿病肾病缬沙坦肾功能影响因素
sulodexidediabetic nephropathyvalsartanrenal functioninfluencing factor
《郑州大学学报(医学版)》 2024 (002)
260-265 / 6
河南省医学科技攻关计划联合共建项目(LHGJ20220988);河南省医学科技攻关计划项目(LHGJ20200948)
评论